Ownership
Private
Therapeutic Areas
Oncology
Stage
Phase 2
Modalities
Small molecule

Valent Technologies General Information

Conducting Phase 2 clinical trials for VAL-083 in glioblastoma multiforme (GBM). Interim data shows dose-dependent survival benefit in refractory GBM patients who failed both temozolomide and Avastin therapy.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Menlo Park, California
United States

Drug Pipeline

VAL-083
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Valent Technologies's pipeline data

Book a demo

Key Partnerships

Guangxi Wuzhou Pharmaceuticals

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Valent Technologies Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Valent Technologies's complete valuation and funding history, request access »